Daijun Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daijun Zhou has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Gaoxing Luo
6 shared publicationsTao Yang
Institute of Burn Research; State Key Laboratory of Trauma, Burn and Combined Injury; Key Laboratory of Proteomics of Chongqing, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China
5 shared publicationsDan He
Department of Oncology, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Chengdu, 610051, China
2 shared publications- Dong Li
Department of Oncology, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China
2 shared publications - Tao Zhang
Department of Oncology, General Hospital of Western Theater Command of PLA, Chengdu, 610083, People's Republic of China
2 shared publications ZhiHui Li
Department of Oncology, General Hospital of Western Theater Command, Chengdu, 610083, China
2 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 25
EML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies
Lung cancer is a malignancy characterized by high global incidence and mortality rates, with approximately 85% of cases classified as non-small cell lung cancer (NSCLC). Advances in molecular biology and targeted therapeutic agents have ushered NSCLC into the era of precision medicine. The echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) fusion gene represents a pivotal target for personalized treatment in NSCLC. Although ALK inhibitors exhibit significant efficacy against EML4-ALK-positive tumors, addressing drug resistance remains a major challenge. Identifying novel therapeutic targets and implementing combination therapies are essential for optimizing subsequent treatment strategies and improving overall prognosis. In the management of patients with EML4-ALK gene fusion, continuous monitoring of tumor progression and timely adjustment of treatment regimens based on disease status are critical to achieving long-term clinical benefits. This review comprehensively summarizes recent advances in the clinicopathological features, targeted drug development, resistance mechanisms, and potential therapeutic targets associated with the EML4-ALK fusion gene.
- 26 June 2026
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 25
Open AccessEML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies
Lung cancer is a malignancy characterized by high global incidence and mortality rates, with approximately 85% of cases classified as non-small cell lung cancer (NSCLC). Advances in molecular biology and targeted therapeutic agents have ushered NSCLC into the era of precision medicine. The echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) fusion gene represents a pivotal target for personalized treatment in NSCLC. Although ALK inhibitors exhibit significant efficacy against EML4-ALK-positive tumors, addressing drug resistance remains a major challenge. Identifying novel therapeutic targets and implementing combination therapies are essential for optimizing subsequent treatment strategies and improving overall prognosis. In the management of patients with EML4-ALK gene fusion, continuous monitoring of tumor progression and timely adjustment of treatment regimens based on disease status are critical to achieving long-term clinical benefits. This review comprehensively summarizes recent advances in the clinicopathological features, targeted drug development, resistance mechanisms, and potential therapeutic targets associated with the EML4-ALK fusion gene.
- Open Access
- 29 July 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102142
Targeted prevention of radiation-induced oral mucositis by glutathione-modified liposome coated K12 probiotics and clinical study
- 29 July 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102142
Open AccessTargeted prevention of radiation-induced oral mucositis by glutathione-modified liposome coated K12 probiotics and clinical study
- Open Access
- 16 October 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-12
Metal-organic-framework-based sitagliptin-release platform for multieffective radiation-induced intestinal injury targeting therapy and intestinal flora protective capabilities
In patients with abdominal or pelvic tumors, radiotherapy can result in radiation-induced intestinal injury (RIII), a potentially severe complication for which there are few effective therapeutic options. Sitagliptin (SI) is an oral hypoglycemic drug that exhibits antiapoptotic, antioxidant, and anti-inflammatory activity, but how it influences RIII-associated outcomes has yet to be established. In this study, a pH-responsive metal-organic framework-based nanoparticle platform was developed for the delivery of SI (SI@ZIF-8@MS NP). These NPs incorporated mPEG-b-PLLA (MS) as an agent capable of resisting the effects of gastric acid, and are capable of releasing Zn2+ ions. MS was able to effectively shield these SI@ZIF-8 NPs from rapid degradation when exposed to an acidic environment, enabling the subsequent release of SI and Zn2+ within the intestinal fluid. Notably, SI@ZIF-8@MS treatment was able to mitigate radiation-induced intestinal dysbiosis in these mice. restored radiation-induced changes in bacterial composition. In summary, these data demonstrate the ability of SI@ZIF-8@MS to protect against WAI-induced intestinal damage in mice, suggesting that these NPs represent a multimodal targeted therapy that can effectively be used in the prevention or treatment of RIII.
- 16 October 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-12
Open AccessMetal-organic-framework-based sitagliptin-release platform for multieffective radiation-induced intestinal injury targeting therapy and intestinal flora protective capabilities
In patients with abdominal or pelvic tumors, radiotherapy can result in radiation-induced intestinal injury (RIII), a potentially severe complication for which there are few effective therapeutic options. Sitagliptin (SI) is an oral hypoglycemic drug that exhibits antiapoptotic, antioxidant, and anti-inflammatory activity, but how it influences RIII-associated outcomes has yet to be established. In this study, a pH-responsive metal-organic framework-based nanoparticle platform was developed for the delivery of SI (SI@ZIF-8@MS NP). These NPs incorporated mPEG-b-PLLA (MS) as an agent capable of resisting the effects of gastric acid, and are capable of releasing Zn2+ ions. MS was able to effectively shield these SI@ZIF-8 NPs from rapid degradation when exposed to an acidic environment, enabling the subsequent release of SI and Zn2+ within the intestinal fluid. Notably, SI@ZIF-8@MS treatment was able to mitigate radiation-induced intestinal dysbiosis in these mice. restored radiation-induced changes in bacterial composition. In summary, these data demonstrate the ability of SI@ZIF-8@MS to protect against WAI-induced intestinal damage in mice, suggesting that these NPs represent a multimodal targeted therapy that can effectively be used in the prevention or treatment of RIII.
- 4 July 2024
- Published by Elsevier in Microbial Pathogenesis
- Vol. 193, 106784
Changes in the gut microbiome of patients with esophageal cancer: A systematic review and meta-analysis based on 16S gene sequencing technology
- 4 July 2024
- Published by Elsevier in Microbial Pathogenesis
- Vol. 193, 106784
Changes in the gut microbiome of patients with esophageal cancer: A systematic review and meta-analysis based on 16S gene sequencing technology
- Open Access
- 1 July 2024
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 19, 7729-7730
Optimization and Integration of Nanosilver on Polycaprolactone Nanofibrous Mesh for Bacterial Inhibition and Wound Healing in vitro and in vivo [Corrigendum]
Corrigendum for the article Optimization and integration of nanosilver on polycaprolactone nanofibrous mesh for bacterial inhibition and wound healing in vitro and in vivo
- 1 July 2024
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 19, 7729-7730
Open AccessOptimization and Integration of Nanosilver on Polycaprolactone Nanofibrous Mesh for Bacterial Inhibition and Wound Healing in vitro and in vivo [Corrigendum]
Corrigendum for the article Optimization and integration of nanosilver on polycaprolactone nanofibrous mesh for bacterial inhibition and wound healing in vitro and in vivo
- Open Access
- 1 September 2022
- Published by IOP Publishing in Materials Research Express
- Vol. 9 (9) , 095003
Preparation of graphene oxide membrane-daptomycin/epidermal growth factor dressing and its effect on wound healing
Herein, a series of environmentally friendly dressings were specially fabricated from graphene oxide (GO) membrane (a high quality substrate with antibacterial function) and Daptomycin (antibacterial function)/Epidermal growth factor (EGF, wound healing function) for the purpose of antibacterial applications. A performance comparison was designed by employing four dressing samples, including the neat GO membrane (Group A), GO membrane-Daptomycin (Group B), GO membrane-EGF (Group C), and GO membrane-Daptomycin/EGF (Group D). The results analyzed using Fourier transform infrared spectroscopy suggested that Daptomycin and EGF might be adhered to the GO membrane. The contact angle test showed that the hydrophilicity of material gradually increased from Group A to Group D. Groups B and D displayed similar in vitro antibacterial activities, better than those of Groups A and C (their antibacterial performances were similar to each other); all the four experimental groups outperformed the control group (P > 0.05). On the other hand, Groups C and D could promote the proliferation effectively within 1–7 days (P < 0.05), and they also showed similar activities in the cell migration, which were higher than those of Groups A and B (close to each other); all the experimental groups outdid the control group (P < 0.05). Moreover, by monitoring the expression levels of PCNA and CD31 , samples from Group D could promote both angiogenesis and cell reproduction when covering the skin defects (P < 0.05). At the seventh days after the injury, the control and experimental groups of A, B, C, and D displayed healing rates of 40.6%, 53.0%, 66.8%, 60.1%, and 68.3%, respectively. Based on a successful fabrication of GO membrane-Daptomycin/EGF dressings, antibacterial effects as well as growth-promoting performance were well realized by samples in Group D. This is benifitial for the wound healing to a great extent.
- 1 September 2022
- Published by IOP Publishing in Materials Research Express
- Vol. 9 (9) , 095003
Open AccessPreparation of graphene oxide membrane-daptomycin/epidermal growth factor dressing and its effect on wound healing
Herein, a series of environmentally friendly dressings were specially fabricated from graphene oxide (GO) membrane (a high quality substrate with antibacterial function) and Daptomycin (antibacterial function)/Epidermal growth factor (EGF, wound healing function) for the purpose of antibacterial applications. A performance comparison was designed by employing four dressing samples, including the neat GO membrane (Group A), GO membrane-Daptomycin (Group B), GO membrane-EGF (Group C), and GO membrane-Daptomycin/EGF (Group D). The results analyzed using Fourier transform infrared spectroscopy suggested that Daptomycin and EGF might be adhered to the GO membrane. The contact angle test showed that the hydrophilicity of material gradually increased from Group A to Group D. Groups B and D displayed similar in vitro antibacterial activities, better than those of Groups A and C (their antibacterial performances were similar to each other); all the four experimental groups outperformed the control group (P > 0.05). On the other hand, Groups C and D could promote the proliferation effectively within 1–7 days (P < 0.05), and they also showed similar activities in the cell migration, which were higher than those of Groups A and B (close to each other); all the experimental groups outdid the control group (P < 0.05). Moreover, by monitoring the expression levels of PCNA and CD31 , samples from Group D could promote both angiogenesis and cell reproduction when covering the skin defects (P < 0.05). At the seventh days after the injury, the control and experimental groups of A, B, C, and D displayed healing rates of 40.6%, 53.0%, 66.8%, 60.1%, and 68.3%, respectively. Based on a successful fabrication of GO membrane-Daptomycin/EGF dressings, antibacterial effects as well as growth-promoting performance were well realized by samples in Group D. This is benifitial for the wound healing to a great extent.
- Open Access
- 18 June 2022
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 20 (1) , 1-14
An IFI6-based hydrogel promotes the healing of radiation-induced skin injury through regulation of the HSF1 activity
Radiation-induced skin injury (RISI) is a common complication of radiotherapy. Interferon-alpha inducible protein 6 (IFI6) significantly reduces the radiation sensitivity of HaCaT cells. Sodium alginate (SA) has substantial moisturizing properties. Graphene oxide (GO) is a suitable substrate with physical antibacterial properties. Therefore, we designed materials to modify IFI6 using the biogule of polydopamine (PDA) connected to GO/SA. The structure, size, morphology, and elemental compositions of IFI6-PDA@GO/SA were analyzed. Cytological studies suggested that IFI6-PDA@GO/SA is non-toxic to HaCaT cells, with antibacterial properties. It promotes migration and vascularization and inhibits apoptosis. These cells express IFI6 after irradiation. The mouse model suggested that IFI6-PDA@GO/SA promotes wound healing and reduces reactive oxygen species expression. IFI6-PDA@GO/SA accelerates RISI healing, possibly by initiating the SSBP1/HSF1 signaling pathway. In addition, IFI6-PDA@GO/SA improves the immune microenvironment. This study constitutes the first use of IFI6 as a RISI wound-healing material.
- 18 June 2022
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 20 (1) , 1-14
Open AccessAn IFI6-based hydrogel promotes the healing of radiation-induced skin injury through regulation of the HSF1 activity
Radiation-induced skin injury (RISI) is a common complication of radiotherapy. Interferon-alpha inducible protein 6 (IFI6) significantly reduces the radiation sensitivity of HaCaT cells. Sodium alginate (SA) has substantial moisturizing properties. Graphene oxide (GO) is a suitable substrate with physical antibacterial properties. Therefore, we designed materials to modify IFI6 using the biogule of polydopamine (PDA) connected to GO/SA. The structure, size, morphology, and elemental compositions of IFI6-PDA@GO/SA were analyzed. Cytological studies suggested that IFI6-PDA@GO/SA is non-toxic to HaCaT cells, with antibacterial properties. It promotes migration and vascularization and inhibits apoptosis. These cells express IFI6 after irradiation. The mouse model suggested that IFI6-PDA@GO/SA promotes wound healing and reduces reactive oxygen species expression. IFI6-PDA@GO/SA accelerates RISI healing, possibly by initiating the SSBP1/HSF1 signaling pathway. In addition, IFI6-PDA@GO/SA improves the immune microenvironment. This study constitutes the first use of IFI6 as a RISI wound-healing material.
- 10 January 2019
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2058 (1) , 020012
Preparation of chitin-lysozyme anti-infective eco-friendly dressing and its effect on wound healing
This study aimed to prepare an anti-infective Eco-friendly dressing of chitin-lysozyme, which should have antibacterial activity in vitro and promote wound healing in vivo. The chitin-lysozyme was prepared using chitin (group Control) and dopamine gule (group A) methods respectively, at 2mg/ml, 4mg/ml, and 8mg /ml (Namely group B, C and D). Finally, the chitin-lysozyme was observed as lysozyme spherical particles and bedding dopamine colloid. FTIR showed that the lysozyme had been adhered and the contact angle test showed that the material was hydrophilic. In vitro antibacterial effect was significant and the role on E. coli was significantly weaker than that on S. aureus. The cytotoxicity of the chitin-lysozyme dressing was not found. On day 7, the healing rates were 35.2%, 37.9%, 56.4%, 71.9% and 75.1% in Group Control, A, B, C and D, respectively. The wound healing rate was higher in the C and D groups than these in the other three groups (P <0.05).
- 10 January 2019
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2058 (1) , 020012
Preparation of chitin-lysozyme anti-infective eco-friendly dressing and its effect on wound healing
This study aimed to prepare an anti-infective Eco-friendly dressing of chitin-lysozyme, which should have antibacterial activity in vitro and promote wound healing in vivo. The chitin-lysozyme was prepared using chitin (group Control) and dopamine gule (group A) methods respectively, at 2mg/ml, 4mg/ml, and 8mg /ml (Namely group B, C and D). Finally, the chitin-lysozyme was observed as lysozyme spherical particles and bedding dopamine colloid. FTIR showed that the lysozyme had been adhered and the contact angle test showed that the material was hydrophilic. In vitro antibacterial effect was significant and the role on E. coli was significantly weaker than that on S. aureus. The cytotoxicity of the chitin-lysozyme dressing was not found. On day 7, the healing rates were 35.2%, 37.9%, 56.4%, 71.9% and 75.1% in Group Control, A, B, C and D, respectively. The wound healing rate was higher in the C and D groups than these in the other three groups (P <0.05).
- 10 January 2019
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2058 (1) , 020034
New material: Translucent Balsa-P-coumaric acid modified lysozyme dressing
Objective: using p-coumaric acid as modifier, dopamine adhesive prepared modified lysozyme, using bacteriostatic circle diameter, bacteria culture and the minimum bacteriostasis concentration bacteriostatic function, the optimal PH, temperature, time, contrast enzymology properties, and hydrophobicity and secondary structure content determination. Methods: the preparation of translucent Balsa, respectively designed for Control group (Control), wood group (A), translucent Balsa group (B), translucent Balsa - lysozyme group (C), translucent Balsa - P-coumaric acid modified lysozyme group (D). Results: (1) the bacteriostatic effect and the minimum inhibitory concentration of the P-coumaric acid-modified lysozyme > P-coumaric acid; The surface hydrophobicity index of the three substances and the stability of the secondary structure were all p-coumaric acid - modified lysozyme > lysozyme > P-coumaric acid; PH = 6, the temperature is 45°C, the response time of 30 min strongest P-coumaric acid modified lysozyme activity; (2) the Drug loading and encapsulation rate of group D were better than that of group C. In terms of the release curve, the release of C and D groups in the 48h group tended to be stable and maximum, and the cumulative release percentage of 72h was 85.2% and 93.8% respectively. (3) in the control group, the growth of staphylococcus aureus and e. coli was basically in line with the normal trend, and the antibacterial activity of e. coli and staphylococcus aureus in each group was D > C > B (P < 0.05). And 1-7 days, different groups had no value inhibition on fibroblasts (P > 0.05); Conclusion: This study successfully optimized the design of modified lysozyme to prepare Translucent Balsa-P-coumaric acid Modified, which has strong antibacterial ability, stable and persistent release, and no cytotoxicity.
- 10 January 2019
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2058 (1) , 020034
New material: Translucent Balsa-P-coumaric acid modified lysozyme dressing
Objective: using p-coumaric acid as modifier, dopamine adhesive prepared modified lysozyme, using bacteriostatic circle diameter, bacteria culture and the minimum bacteriostasis concentration bacteriostatic function, the optimal PH, temperature, time, contrast enzymology properties, and hydrophobicity and secondary structure content determination. Methods: the preparation of translucent Balsa, respectively designed for Control group (Control), wood group (A), translucent Balsa group (B), translucent Balsa - lysozyme group (C), translucent Balsa - P-coumaric acid modified lysozyme group (D). Results: (1) the bacteriostatic effect and the minimum inhibitory concentration of the P-coumaric acid-modified lysozyme > P-coumaric acid; The surface hydrophobicity index of the three substances and the stability of the secondary structure were all p-coumaric acid - modified lysozyme > lysozyme > P-coumaric acid; PH = 6, the temperature is 45°C, the response time of 30 min strongest P-coumaric acid modified lysozyme activity; (2) the Drug loading and encapsulation rate of group D were better than that of group C. In terms of the release curve, the release of C and D groups in the 48h group tended to be stable and maximum, and the cumulative release percentage of 72h was 85.2% and 93.8% respectively. (3) in the control group, the growth of staphylococcus aureus and e. coli was basically in line with the normal trend, and the antibacterial activity of e. coli and staphylococcus aureus in each group was D > C > B (P < 0.05). And 1-7 days, different groups had no value inhibition on fibroblasts (P > 0.05); Conclusion: This study successfully optimized the design of modified lysozyme to prepare Translucent Balsa-P-coumaric acid Modified, which has strong antibacterial ability, stable and persistent release, and no cytotoxicity.
- 10 January 2019
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2058 (1) , 020022
Preparation and evaluation of translucent Balsa-Caffeic acid modified lysozyme dressing
Objective: using caffeic acid as modifier, dopamine adhesive prepared modified lysozyme, using bacteriostatic circle diameter, bacteria culture and the minimum bacteriostasis concentration bacteriostatic function, the optimal PH, temperature, time, contrast enzymology properties, and hydrophobicity and secondary structure content determination. Methods: the preparation of translucent Balsa, respectively designed for Control group (Control), wood group (A), translucent Balsa group (B), translucent Balsa - lysozyme group (C), translucent Balsa - Caffeic acid modified lysozyme group (D). Results: (1) the bacteriostatic effect and the minimum inhibitory concentration of the Caffeic acid-modified lysozyme > Caffeic acid; The surface hydrophobicity index of the three substances and the stability of the secondary structure were all caffeic acid - modified lysozyme > lysozyme > Caffeic acid; PH=6, the temperature is 50°C, the response time of 30 min strongest Caffeic acid modified lysozyme activity; (2) the Drug loading and encapsulation rate of group D were better than that of group C. In terms of the release curve, the release of C and D groups in the 48h group tended to be stable and maximum, and the cumulative release percentage of 72h was 85.2% and 90.5% respectively. (3) in the control group, the growth of staphylococcus aureus and e. coli was basically in line with the normal trend, and the antibacterial activity of e. coli and staphylococcus aureus in each group was D>C>B (P0.05); this study successfully optimized the design of modified lysozyme to prepare Translucent Balsa-Caffeic Acid Modified, which has strong antibacterial ability, stable and persistent release, and no cytotoxicity.
- 10 January 2019
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2058 (1) , 020022
Preparation and evaluation of translucent Balsa-Caffeic acid modified lysozyme dressing
Objective: using caffeic acid as modifier, dopamine adhesive prepared modified lysozyme, using bacteriostatic circle diameter, bacteria culture and the minimum bacteriostasis concentration bacteriostatic function, the optimal PH, temperature, time, contrast enzymology properties, and hydrophobicity and secondary structure content determination. Methods: the preparation of translucent Balsa, respectively designed for Control group (Control), wood group (A), translucent Balsa group (B), translucent Balsa - lysozyme group (C), translucent Balsa - Caffeic acid modified lysozyme group (D). Results: (1) the bacteriostatic effect and the minimum inhibitory concentration of the Caffeic acid-modified lysozyme > Caffeic acid; The surface hydrophobicity index of the three substances and the stability of the secondary structure were all caffeic acid - modified lysozyme > lysozyme > Caffeic acid; PH=6, the temperature is 50°C, the response time of 30 min strongest Caffeic acid modified lysozyme activity; (2) the Drug loading and encapsulation rate of group D were better than that of group C. In terms of the release curve, the release of C and D groups in the 48h group tended to be stable and maximum, and the cumulative release percentage of 72h was 85.2% and 90.5% respectively. (3) in the control group, the growth of staphylococcus aureus and e. coli was basically in line with the normal trend, and the antibacterial activity of e. coli and staphylococcus aureus in each group was D>C>B (P0.05); this study successfully optimized the design of modified lysozyme to prepare Translucent Balsa-Caffeic Acid Modified, which has strong antibacterial ability, stable and persistent release, and no cytotoxicity.